2nd Vaccine Global Congress - also Virtual

This most authoritative vaccine congress will be held December 7-9 2008, in Boston MA, USA


Amsterdam, December 3, 2008 – Next week the Elsevier Journal Vaccine, the most comprehensive and pre-eminent journal for those interested in vaccines and vaccination, will organize the 2nd Vaccine Global Congress in Boston MA, USA. For those people who cannot attend the congress in Boston, Elsevier is organizing the 1st Vaccine Virtual Congress powered by ON24, the leading provider of webcasting and virtual events solutions. This truly interactive event will allow people to sample the high-quality content and networking opportunities that the congress and exhibition provide from their desk.

Following the successful Vaccine Congress held in Amsterdam last year, the meeting in Boston will again serve as an authoritative international interface between academics in research and development, regulatory and governmental agencies, charities, and health and industry professionals. The 2nd Vaccine Global Congress is organized in collaboration with the International Society for Vaccines. To supplement a number of invited keynote speakers, multiple oral and poster presentations have been selected to cover all facets of vaccinology, including: human vaccines for infectious and non-infectious diseases, veterinary vaccines, adjuvants, drug delivery, production, safety and regulatory aspects.

In addition, for all of those who cannot join the congress in Boston, Elsevier is offering a taste of the 2nd Vaccine Global Congress by broadcasting live keynote presentations and related Q&A, scheduled on the 9th of December. People will be able to submit questions in real time, network and chat with their online peers, and navigate the show via a virtual fully interactive platform. Registration for the Vaccine Virtual Congress is free.

“As for last year, our aim is to provide a progressive state-of the-art report for scientists, governmental authorities and healthcare workers”, stated Floris de Hon, Publisher of Vaccine, “I am confident that together with the virtual information solution we offer, an event will be created that will assist in accelerating progress in the development of vaccines”.

---

Notes to editors:If you are planning to attend the 2nd Vaccine Global Congress, December 7-9 2008, in Boston, MA, USA, we would be delighted to offer you a registration badge at no charge. A press room will be available and please contact the press office if you are interested in setting up interviews with key opinion leaders in the field of vaccines.

About Vaccine
Vaccine
is the pre-eminent journal for those interested in vaccines and vaccination. It serves as an interface between academics, those in research and development, and workers in the field. Relevant topics range from basic research through to applications, safety and legislation.

About Elsevier
As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems.

In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders.

Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com.

Media Contact
Anna Hogrebe
Elsevier
+31 20 485 3269
newsroom@elsevier.com